Panelists include leaders in the fields of science, medicine and technology: Jack Hidary, Dr. Edward Neilan, Dr. Shoshana Shendelman, Dr. John Greely, Louis ReesePanelists include leaders in the fields of science, medicine and technology: Jack Hidary, Dr. Edward Neilan, Dr. Shoshana Shendelman, Dr. John Greely, Louis Reese

Inaugural Cures Conference to be held on Thursday, February 5, 2026 in NYC

Panelists include leaders in the fields of science, medicine and technology: Jack Hidary, Dr. Edward Neilan, Dr. Shoshana Shendelman, Dr. John Greely, Louis Reese and Nadia Harhen.

NEW YORK, Jan. 21, 2026 /PRNewswire/ — Introducing the inaugural Cures Conference to be held in NYC on Thursday, February 5, 2026. 

The Cures Conference convenes scientists, physicians, pharmaceutical executives, tech leaders, and government officials to leverage their collective expertise—highlighting innovations, advancing understanding, accelerating treatment development, and driving real-world implementation.

Panel discussions will include topics such as:

  • How artificial intelligence can accelerate innovation;
  • How advances in technology can translate to access to medicines for all; and
  • How we can improve health outcomes globally

Noted Panelists:

Jack Hidary  
Jack Hidary is the CEO of SandboxAQ, with a focus on enterprise SaaS solutions at the convergence of AI and Quantum tech.

Dr. Edward Neilan MD, PhD
Dr. Edward “Ed” Neilan is the Chief Medical and Scientific Officer of the National Organization for Rare Disorders (NORD®). Ed is a physician-scientist and rare disease expert.

Dr. Shoshana Shendelman PhD
Dr. Shoshana Shendelman is a scientist and entrepreneur who has founded numerous biotech companies. She is a pioneer in the development of drugs for rare and underserved diseases. Currently she is Vice Chair of the Board of Advisors at Columbia University Medical Center and Columbia University Vagelos College of Physicians and Surgeons. 

Dr. John Greally MD
Dr. John Greally is the Chief of the Division of Genomics, at Albert Einstein College of Medicine; Director, New York Center for Rare Diseases (NYCRD); Director, Center for Epigenomics, Albert Einstein College of Medicine; and Professor of Genetics and Pediatrics, Albert Einstein College of Medicine. Dr. Greally is a specialist in clinical genetics, with an emphasis on rare and congenital diseases. 

Louis Reese
Lou Reese is a co-founder, CEO and member of Board of Directors at United Neuroscience.

Nadia Harhen
Nadia Harhen is the General manager of AI Simulation at SandboxAQ. By combining the versatility of AI with the accuracy of quantum simulation, she is radically shifting the rate and cost of drug, material, and chemical discovery.

The Cures Conference will be held at The Ned, 1170 Broadway, New York, New York.  For more information, visit https://curesconference.com. Please contact Sam Sohaili at sam@dmaunited.com for registration and attendance information.

For Press Inquiries:
nancyc@dmaunited.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inaugural-cures-conference-to-be-held-on-thursday-february-5-2026-in-nyc-302667523.html

SOURCE DMA United

Market Opportunity
John Tsubasa Rivals Logo
John Tsubasa Rivals Price(JOHN)
$0.00702
$0.00702$0.00702
-0.14%
USD
John Tsubasa Rivals (JOHN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

qLabs Fires First Shot in Quantum Crypto Race — Can Coinbase Catch Up?

qLabs Fires First Shot in Quantum Crypto Race — Can Coinbase Catch Up?

The rapid progress of quantum computing is forcing the cryptocurrency industry to confront the problem that has long been treated as theoretical. Blockchains th
Share
CryptoNews2026/01/30 22:53
The Anatomy of a Self-Made Billionaire’s Mindset: How Gurhan Kiziloz Reached a $1.7B Net Worth

The Anatomy of a Self-Made Billionaire’s Mindset: How Gurhan Kiziloz Reached a $1.7B Net Worth

There are many paths to wealth in the modern economy, but the one Gurhan Kiziloz took stands out for a simple reason: he built everything himself. By 2026, the
Share
Coinstats2026/01/30 23:07
Aave DAO to Shut Down 50% of L2s While Doubling Down on GHO

Aave DAO to Shut Down 50% of L2s While Doubling Down on GHO

The post Aave DAO to Shut Down 50% of L2s While Doubling Down on GHO appeared on BitcoinEthereumNews.com. Aave DAO is gearing up for a significant overhaul by shutting down over 50% of underperforming L2 instances. It is also restructuring its governance framework and deploying over $100 million to boost GHO. This could be a pivotal moment that propels Aave back to the forefront of on-chain lending or sparks unprecedented controversy within the DeFi community. Sponsored Sponsored ACI Proposes Shutting Down 50% of L2s The “State of the Union” report by the Aave Chan Initiative (ACI) paints a candid picture. After a turbulent period in the DeFi market and internal challenges, Aave (AAVE) now leads in key metrics: TVL, revenue, market share, and borrowing volume. Aave’s annual revenue of $130 million surpasses the combined cash reserves of its competitors. Tokenomics improvements and the AAVE token buyback program have also contributed to the ecosystem’s growth. Aave global metrics. Source: Aave However, the ACI’s report also highlights several pain points. First, regarding the Layer-2 (L2) strategy. While Aave’s L2 strategy was once a key driver of success, it is no longer fit for purpose. Over half of Aave’s instances on L2s and alt-L1s are not economically viable. Based on year-to-date data, over 86.6% of Aave’s revenue comes from the mainnet, indicating that everything else is a side quest. On this basis, ACI proposes closing underperforming networks. The DAO should invest in key networks with significant differentiators. Second, ACI is pushing for a complete overhaul of the “friendly fork” framework, as most have been unimpressive regarding TVL and revenue. In some cases, attackers have exploited them to Aave’s detriment, as seen with Spark. Sponsored Sponsored “The friendly fork model had a good intention but bad execution where the DAO was too friendly towards these forks, allowing the DAO only little upside,” the report states. Third, the instance model, once a smart…
Share
BitcoinEthereumNews2025/09/18 02:28